Matches in Wikidata for { <http://www.wikidata.org/entity/Q80194230> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q80194230 description "article scientifique publié en 2007" @default.
- Q80194230 description "artículu científicu espublizáu en marzu de 2007" @default.
- Q80194230 description "im März 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80194230 description "scientific article published on 23 March 2007" @default.
- Q80194230 description "wetenschappelijk artikel" @default.
- Q80194230 description "наукова стаття, опублікована в березні 2007" @default.
- Q80194230 name "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 name "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 type Item @default.
- Q80194230 label "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 label "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 prefLabel "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 prefLabel "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 P1433 Q80194230-70CF3103-69ED-4FA6-B86A-EE8CEE1E2606 @default.
- Q80194230 P1476 Q80194230-546A59DC-8ED0-40D5-8E17-0B5170641383 @default.
- Q80194230 P2093 Q80194230-34B36449-9114-43DF-A32F-18ECEB41D7D9 @default.
- Q80194230 P2093 Q80194230-E610D549-A3D9-4A98-9B52-8AC318E23238 @default.
- Q80194230 P304 Q80194230-A5BCBB69-337B-4256-9BA4-4B9EE69D6F5C @default.
- Q80194230 P31 Q80194230-B7555389-0B2F-4A35-974C-D16098EF7E4E @default.
- Q80194230 P356 Q80194230-DEB1C319-5963-4F93-B546-DEB49FB26CF1 @default.
- Q80194230 P433 Q80194230-02AFFFB9-FA4D-466B-A336-1D8F3A496BE7 @default.
- Q80194230 P478 Q80194230-73B15287-08F7-483F-B5CF-22416DBE2193 @default.
- Q80194230 P577 Q80194230-58C3392E-4E7A-4934-9D63-44C4410A4589 @default.
- Q80194230 P698 Q80194230-85DF07DE-D9F5-4B16-AC4B-CD32BFC895EE @default.
- Q80194230 P356 J.CCT.2007.03.008 @default.
- Q80194230 P698 17449334 @default.
- Q80194230 P1433 Q5164971 @default.
- Q80194230 P1476 "Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials" @default.
- Q80194230 P2093 "Jinping Wang" @default.
- Q80194230 P2093 "William Mietlowski" @default.
- Q80194230 P304 "674" @default.
- Q80194230 P31 Q13442814 @default.
- Q80194230 P356 "10.1016/J.CCT.2007.03.008" @default.
- Q80194230 P433 "5" @default.
- Q80194230 P478 "28" @default.
- Q80194230 P577 "2007-03-23T00:00:00Z" @default.
- Q80194230 P698 "17449334" @default.